New pill targets Hard-to-Treat cancers with PIK3CA mutation
NCT ID NCT07407504
First seen Feb 16, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This study tests a new drug called GenSci145 in people with advanced solid tumors that have a specific mutation in the PIK3CA gene. The trial has two parts: first, finding a safe dose, then seeing if it shrinks tumors. About 186 adults aged 18-75 will take the drug alone or with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH PIK3CA-MUTATED are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Cancer Hospital of the Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GenSci145 tablets
What this could lead to
If successful, this could point toward a new targeted treatment option for people with certain gene-mutated advanced cancers.
What could go wrong
This is an early phase 1/2 trial, so safety and dosing are still being figured out. It may not work or could have side effects, and it only applies to a specific genetic mutation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.